MAM
Samsung to standardise LCD panels for mass TV market
MUMBAI: Samsung Electronics, which claims to be the world’s largest provider of thin-film transistor liquid crystal display (LCD) panels is accelerating its plans to standardise on 40″ and 46″ LCD panels for the mass TV market.
Rallying behind the 40″ and 46″ sizes, Samsung will begin installing critical equipment at a new LCD production line, Line 7-2, to produce a glass substrate identical to the one at its nearby joint venture (S-LCD) production facility with Sony Corporation.
By replicating the substrate size (1870 x 2200 mm) of the S-LCD (Line 7-1) Line, the company is moving aggressively to assume a strong leadership position in large LCD panel supply worldwide through standardization of high definition LCD TVs targeting living room environments.
The 1870 x 2200 mm substrate is ideally suited for 40″ and 46″ TV panels. From a single plate, eight 40″ panels or six 46″ panels can be produced simultaneously. By committing to standardized state-of–the art 7G production, Samsung expects not only to lead standardisation of the large LCD TV market, including 40″ and 46″ TV panel sizes, but also to quicken its pace into a full-scale sales expansion.
With its embrace of 40″ and 46″ LCD TV sizes, Samsung is well positioned to provide a stable supply for its growing customer base, which demands high-quality, large LCD TV panels at very competitive price points. The company plans to begin mass production at Line 7-2, optimized for 40″ and 46″ LCD TV panels, in April 2006. When fully ramped, Line 7-2 will produce 45,000 sheets per month.
The new line, which will cost approximately $ 975 million to build, consists of a FAB facility area of 300,000 square meters and a module facility area of 93,000 square meters.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
